Panel Spotlight: AI in Drug Discovery and Development

30 Jul

By Rory McCann, Marketing Manager & Conference Producer, LSN

Life Science Nation (LSN) has been busy this summer recruiting panelists for its Inaugural 4D Meets AI partnering conference, exploring the impact of Artificial Intelligence (AI) on Drugs, Devices, Diagnostics, and Digital Health (the 4 Ds), while facilitating conversations between early-stage companies and strategic partners.

We are pleased to introduce the AI in Drug Discovery and Development panel, discussing repurposing existing drugs and identifying, optimizing, and validating new drug candidates. This panel features five leaders in this area coming together to lead a discussion on their work in the field, predictions moving forward, and best practices to bring AI-driven therapeutics to the patients who need it most. Get to know them, and then register to join the conversation September 17-18.

Andrew Satz, MS, Co-Founder & CEO, EVQLV (Moderator)

Andrew Satz is the CEO and Co-Founder of EVQLV, a technology company leveraging AI to accelerate the speed and lower the failure rates of biologics discovery and development. He co-developed EVQLV’s biologics discovery engine, which uses a wide range of machine learning and software engineering techniques to design and screen novel biologics. A data scientist by training, Satz is a seasoned entrepreneur and technologist having founded multiple startups and holding leadership roles in companies ranging from insurance to biotech. Satz holds a BA in Economics and MS in Data Science, both from Columbia University.

Gini Deshpande, PhD, Founder & CEO, NuMedii

Gini Deshpande, PhD, is the founder and CEO of NuMedii, a data-driven drug discovery company that pioneered the use of artificial intelligence and advanced data sciences to rapidly discover new precision therapeutics. Having raised the company’s financing and overseen successful partnerships with several large pharma companies, she is now spearheading the company’s efforts in the development of its own pipeline in fibrosis and orphan oncology indications. Previously, she helped Affymetrix and other companies with market development strategies for their innovative technologies. She led intrapreneurial efforts at Children’s Hospital Boston for the creation of new devices for the tiniest of patients and vaccines for the developing world. Gini has also helped commercialize early-stage life science technologies in research tools, diagnostics & therapeutics and has closed licensing deals worth several million. Gini received her PhD in Biological Sciences from Purdue University and did post-doctoral work at Massachusetts General Hospital.

Irwin Gelman, MPh, PhD, Founder, Veronomics, Inc.

Veronomics, Inc. is a Delaware C Corporation (registered in New York State) headquartered in the University at Buffalo New York State Center of Excellence in Bioinformatics and Life Sciences. The company was founded by Irwin H. Gelman, PhD, who is a Distinguished Professor of Oncology and Director of Research Integration in the Roswell Park Comprehensive Cancer Center, and Track Chair of the UB-Roswell Park academic program in Cancer Genetics, Genomics and Development. Dr. Gelman received his BA in Biochemistry at Wesleyan University, MA, MPh and PhD degrees from Columbia University, and was an American Cancer Society Postdoctoral Associate in the lab of Prof. Hidesaburo Hanafusa at The Rockefeller University. Dr. Gelman has been involved with two biotech startups currently traded on the NASDAQ, Antigenics LLC (now Agenus) and Kinex Pharmaceuticals (now Athenex), where he helped develop the Src-family kinase inhibitors, KX2-391 and KX2-361, now in Phase II and III clinical trials for several cancers.

Rafael Rosengarten, PhD, Co-Founder & CEO, Genialis, Inc.

Rafael leads Genialis’ effort to integrate and mine vast and diverse sources of biomedical knowledge to realize the promise of precision medicine and therapeutic discovery. He spent nearly 20 years in biomedical research prior to Genialis, publishing on the evolution of innate immune systems, bioengineering of microbes, and genetics of development. Rafael co-invented the j5 DNA assembly design automation software for high-throughput molecular design and analyses (since commercialized by TeselaGen). Rafael earned his doctorate at Yale University, and conducted postdoctoral research at Lawrence Berkeley National Laboratory’s Joint BioEnergy Institute (JBEI) and Baylor College of Medicine. In his free time, Rafael enjoys cooking and rock-climbing, and raising heirloom tomatoes and two precocious children.

Nabiha Saklayen, PhD, Co-Founder & CEO, Cellino Biotech, Inc.

Nabiha Saklayen is a bio-inspired physicist and entrepreneur. Nabiha launched Cellino to converge physics, biology, and machine learning to enable paradigm shifts in regenerative medicine. Cellino is building the next generation of cell and tissue therapies with a proprietary platform technology that makes stem cell-derived therapies scalable for the first time. Nabiha was recognized as a Pioneer in MIT Tech Review’s 35 Innovators under 35 list for her inventions in laser-based delivery methods and is on the 2019 Forbes under 30 List for Healthcare. She received her PhD in Physics from Harvard University as an HHMI International Fellow. She made significant scientific contributions to the field of pulsed-laser delivery to cells, with several peer-reviewed papers published, patents pending, and grants awarded. Nabiha grew up in Saudi Arabia, Bangladesh, Germany, and Sri Lanka.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: